Control - UFH

ApprovedSmall molecule

GSK

Control - UFH is one of 109 small molecule programs targeting Acute Myocardial Infarction. It is currently in Approved.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

TuberculosisActive, not recruiting

Acute Myocardial InfarctionPhase 3

Active, not recruiting

COVID-19Phase 2

Active, not recruiting

InfluenzaApproved

Active, not recruiting

TuberculosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Control - UFH

GSK

Approved

1 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Aldactone

Pfizer

Preclinical

1 4

Nexavar

Bayer

Preclinical

1 5

Benadryl

PParkedale

Preclinical

1 6

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 7

Rayaldee

OOrganon and Co

Preclinical

1 8

Olokizumab

UCB

Preclinical

1 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Biological Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tuberculosis2 trials

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

Completed· GSK logo

GSK·Phase 2·NCT00707967·37 enrolled

Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults

Completed· GSK logo

GSK·Phase 2·NCT00397943·110 enrolled

COVID-191 trial

A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults

Completed· GSK logo

GSK·Phase 2·NCT05960097·692 enrolled

Influenza1 trial

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza

Completed·BButantan Institute·Phase 4·NCT01693380·1,742 enrolled

Enterovirus 71 Inactivated Vaccine1 trial

An Immunity Persistence Study of Enterovirus 71 Inactivated Vaccine (Vero Cell)

Unknown status· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 4·NCT05397587·474 enrolled

Immunogenicity1 trial

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)

Completed·HHualan Biological Bacterin Co. Ltd.·Phase 3·NCT06177249·1,956 enrolled

2 more indications

Single Dose1 trial

Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)

Completed·IInternational Vaccine Institute·Phase 3·NCT04204096·1,800 enrolled

Acute Myocardial Infarction1 trial

OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction

Completed· GSK logo

GSK·Phase 3·NCT00064428·12,092 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Control - UFH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Control - UFH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Control - UFH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GSK

Control - UFH

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tuberculosis2 trials

COVID-191 trial

Influenza1 trial

Enterovirus 71 Inactivated Vaccine1 trial

Immunogenicity1 trial

Single Dose1 trial

Acute Myocardial Infarction1 trial

References

Drug Info

Quick Facts

Related News